Tempus AI (Nasdaq: TEM) moved higher after presenting new AI and precision medicine updates at ASCO 2026.
‍

Investor attention appears focused on Tempus’ ASCO presentation, which highlights how its AI tools could help doctors interpret cancer data, identify treatment options, and connect patients with clinical trials. 

‍

Key details:
‍

• Event: 2026 American Society of Clinical Oncology annual meeting
• ASCO activity: 37 accepted presentations
• Focus areas: AI pathology, RNA treatment response models, ctDNA profiling, minimal residual disease testing, immunotherapy prediction, and multiomics research
• New products/updates: whole-genome sequencing assay, next-gen Tempus Lens AI, AI upgrades to Tempus Hub
• Pelosi angle: 50 TEM call options disclosed in January 2025, exercised into 5,000 shares in January 2026
• Stock move: TEM up about 10%
  ‍

The more interesting part is how Tempus is positioning itself.
‍

This is not just “AI for healthcare” branding. Tempus is trying to build the data layer for oncology decisions: genomic testing, clinical history, tumor biology, treatment patterns, trial matching, and pharma research tools.
‍

For doctors, the value is faster decision support. Instead of manually piecing together molecular data, patient records, and treatment options, Tempus wants to make that information easier to interpret in one place.
‍

For pharma companies, the value is data. Tempus can help analyze real-world clinical and genomic information, identify patient subgroups, study treatment response, and support drug development decisions.
‍

The market opportunity is why investors care. Tempus is targeting several large categories at once: precision medicine, AI oncology, diagnostics, clinical trial matching, and pharma analytics.
‍

Some scale markers:
‍

• More than 5.4 million research records
• Over 200 petabytes of clinical and molecular data
• Connections to roughly 60% of U.S. academic medical centers
• Relationships with about 95% of top pharma companies
  ‍

The risk is that Tempus still needs to prove it can turn this data advantage into durable revenue growth, better margins, and a defensible AI healthcare platform.
‍

Investors will be watching whether Tempus can turn its data advantage and new AI oncology tools into sustained growth as the precision medicine market expands.
‍

Not financial advice.